Altimmune, Inc. financial data

Symbol
ALT on Nasdaq
Industry
Pharmaceutical Preparations
Location
910 Clopper Road, Suite 201 S, Gaithersburg, MD
State of incorporation
DE
Fiscal year end
December 31
Former names
PHARMATHENE, INC (to 5/3/2017), HEALTHCARE ACQUISITION CORP (to 10/15/2007)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.41K % +0.59%
Debt-to-equity 11.4 % +14.8%
Return On Equity -65.3 % -25.5%
Return On Assets -58.6 % -23.8%
Operating Margin -516K % -2191%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77M shares +8.63%
Common Stock, Shares, Outstanding 72.4M shares +2.37%
Entity Public Float 469M USD +154%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 71M shares +33.3%
Weighted Average Number of Shares Outstanding, Diluted 71M shares +33.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 20K USD -95.3%
Research and Development Expense 82.2M USD +25%
General and Administrative Expense 21M USD +15.6%
Operating Income (Loss) -103M USD -7.55%
Nonoperating Income (Expense) 8.11M USD +8.43%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.7M USD +12.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -95.1M USD -7.48%
Earnings Per Share, Basic -1.34 USD/shares +19.3%
Earnings Per Share, Diluted -1.34 USD/shares +19.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.9M USD -72.7%
Assets, Current 137M USD -34.5%
Property, Plant and Equipment, Net 413K USD -36.6%
Operating Lease, Right-of-Use Asset 1.64M USD +352%
Intangible Assets, Net (Excluding Goodwill) 0 USD
Other Assets, Noncurrent 1.64M USD +352%
Assets 139M USD -33.9%
Accounts Payable, Current 211K USD -89.8%
Employee-related Liabilities, Current 3.08M USD -7.12%
Liabilities, Current 10.5M USD -13.8%
Operating Lease, Liability, Noncurrent 1.4M USD +701%
Other Liabilities, Noncurrent 22K USD -45%
Liabilities 15.8M USD -4.49%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.97M USD +0.62%
Retained Earnings (Accumulated Deficit) -561M USD -20.4%
Stockholders' Equity Attributable to Parent 124M USD -36.4%
Liabilities and Equity 139M USD -33.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.4M USD +15.7%
Net Cash Provided by (Used in) Financing Activities -261K USD +13.6%
Net Cash Provided by (Used in) Investing Activities -39.5M USD -397%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 72.4M shares +2.37%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -56.1M USD -776%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 37M USD -72.6%
Deferred Tax Assets, Valuation Allowance 106M USD +28.3%
Deferred Tax Assets, Gross 107M USD +28.7%
Operating Lease, Liability 1.68M USD +151%
Depreciation 107K USD -14.4%
Payments to Acquire Property, Plant, and Equipment 51K USD +467%
Lessee, Operating Lease, Liability, to be Paid 2.13M USD +204%
Property, Plant and Equipment, Gross 2.63M USD 0%
Operating Lease, Liability, Current 279K USD -43.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 376K USD +114%
Lessee, Operating Lease, Liability, to be Paid, Year One 422K USD -19.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +27.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 450K USD +1352%
Lessee, Operating Lease, Liability, to be Paid, Year Three 387K USD
Deferred Tax Assets, Operating Loss Carryforwards 64.8M USD +19.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 700K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 398K USD
Operating Lease, Payments 100K USD 0%
Additional Paid in Capital 690M USD +3.67%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 451K USD +360%
Share-based Payment Arrangement, Expense 14.4M USD +35.3%
Interest Expense 34K USD -50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%